FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163082016> ?p ?o ?g. }

• W2163082016 endingPage "147" @default.
• W2163082016 startingPage "142" @default.
• W2163082016 abstract "Approximately 130 million to 170 million individuals worldwide, including 3.2 million Americans, are infected with chronic hepatitis C virus (HCV), making it the most common blood-borne disease.1,2 Chronic HCV infection is a silent epidemic; the disease can remain quiescent for decades before clinically significant symptoms appear.3The prevalence of HCV and its complications are expected to rise as Americans who are currently living with HCV enter their 50s and 60s.4 Research indicates that by 2015, more than 3 million individuals will have HCV infection that has been present for 20 years or more, which will result in a significant increase in the incidence of advanced liver disease, including cirrhosis, decompensated cirrhosis, and liver cancer.5,6 The Centers for Disease Control and Prevention estimates that for every 100 individuals infected with HCV, 1 to 5 will die from liver cancer or cirrhosis.1In addition to causing substantial morbidity and mortality, HCV is associated with significant financial consequences.3,7 A 2000 study estimated that between 2010 and 2019, the direct medical expenditures for HCV-related conditions will reach nearly $11 billion, the cost of morbidity from disability related to decompensated cirrhosis and hepatocellular carcinoma would reach approximately $21 billion, and the societal cost of premature mortality for patients aged <65 years will exceed $54 billion (in 1999 US dollars).7HCV is currently the only chronic viral infection that is curable with antiviral therapy. The goals of current anti-HCV approaches are to eradicate infection, to avoid complications, and to prevent the spread of HCV to others.8In the early 1990s, single-agent interferon was the standard of care for patients with HCV infection. Single-agent interferon represented a significant therapeutic advancement, because until then there was no treatment available for HCV infection; however, single-agent interferon offered a sustained virologic response (SVR) rate of less than 10% in patients with HCV genotype 1, the most common HCV subtype.8 Interferon was then used in combination with ribavirin, increasing the SVR rate by another 14% to 22%.8 In the early 2000s, once-weekly pegylated forms of interferon were introduced. The combination of pegylated interferon with ribavirin increased SVR rates to more than 50% in patients with HCV genotype 1. However, HCV genotype 1 was less responsive than HCV genotype 2 or 3.9,10 Because of this variability in HCV response, low response rates in common HCV subpopulations (ie, black patients, patients with cirrhosis), and side effects associated with interferon and ribavirin, there remained a need to develop novel antiviral therapies.8The treatment options for patients with HCV have evolved significantly in the past several years. In 2011, 2 first-generation protease inhibitors, telaprevir and boceprevir (also known as direct-acting antiviral drugs), were approved by the US Food and Drug Administration (FDA).11,12 Both agents offered significant efficacy in patients with HCV genotype 1 infection as measured by SVR rates.11,12In December 2013, the FDA approved sofosbuvir (Sovaldi) in combination with ribavirin—the first interferon-free, all-oral regimen—for the treatment of patients with HCV genotype 2 or 3.13,14 In addition, sofosbuvir in combination with interferon and ribavirin is approved for the treatment of patients with HCV genotype 1 and genotype 4.13,14 Candidates for sofosbuvir therapy include patients with hepatocellular carcinoma who meet Milan criteria (ie, awaiting liver transplantation) and patients with HCV/HIV-1 coinfection.13,14 Sofosbuvir regimens require less treatment time than older combination regimens—12 weeks for patients with HCV genotype 1, 2, or 4; and 24 weeks for patients with HCV genotype 3.14In October 2014, the FDA approved the fixed-dose combination capsule of ledipasvir and sofosbuvir (Harvoni) for the treatment of patients with HCV genotype 1 infection.15 This once-daily combination tablet was the first regimen approved for HCV genotype 1 without interferon or ribavirin.15Interest in novel therapies for HCV remain strong in light of the increasing incidence of HCV (and its costly complications), unmet patient needs, and the identification of new drug targets.16 Efforts continue, with the goals of improving the pharmacokinetics and the tolerability of these agents, as well as determining treatment strategies––interferon-containing and interferon-free (all oral) regimens––that optimize outcomes.17" @default.
• W2163082016 created "2016-06-24" @default.
• W2163082016 creator A5091035853 @default.
• W2163082016 date "2015-04-16" @default.
• W2163082016 modified "2023-09-24" @default.
• W2163082016 title "Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection." @default.
• W2163082016 cites W1587896012 @default.
• W2163082016 cites W1973675889 @default.
• W2163082016 cites W2003104968 @default.
• W2163082016 cites W2027545702 @default.
• W2163082016 cites W2042158802 @default.
• W2163082016 cites W2042899087 @default.
• W2163082016 cites W2043193067 @default.
• W2163082016 cites W2113428683 @default.
• W2163082016 cites W2127685726 @default.
• W2163082016 cites W2127863284 @default.
• W2163082016 cites W2145814334 @default.
• W2163082016 cites W2153177038 @default.
• W2163082016 cites W82283456 @default.
• W2163082016 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4665049" @default.
• W2163082016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26629280" @default.
• W2163082016 hasPublicationYear "2015" @default.
• W2163082016 type Work @default.
• W2163082016 sameAs 2163082016 @default.
• W2163082016 citedByCount "26" @default.
• W2163082016 countsByYear W21630820162015 @default.
• W2163082016 countsByYear W21630820162016 @default.
• W2163082016 countsByYear W21630820162017 @default.
• W2163082016 countsByYear W21630820162018 @default.
• W2163082016 countsByYear W21630820162019 @default.
• W2163082016 countsByYear W21630820162023 @default.
• W2163082016 crossrefType "journal-article" @default.
• W2163082016 hasAuthorship W2163082016A5091035853 @default.
• W2163082016 hasConcept C126322002 @default.
• W2163082016 hasConcept C142462285 @default.
• W2163082016 hasConcept C203014093 @default.
• W2163082016 hasConcept C2522874641 @default.
• W2163082016 hasConcept C2776408679 @default.
• W2163082016 hasConcept C2776455275 @default.
• W2163082016 hasConcept C2777075537 @default.
• W2163082016 hasConcept C2777100407 @default.
• W2163082016 hasConcept C2777214474 @default.
• W2163082016 hasConcept C2778019345 @default.
• W2163082016 hasConcept C2778785139 @default.
• W2163082016 hasConcept C2778867932 @default.
• W2163082016 hasConcept C2779298103 @default.
• W2163082016 hasConcept C2780040827 @default.
• W2163082016 hasConcept C2993143319 @default.
• W2163082016 hasConcept C71924100 @default.
• W2163082016 hasConceptScore W2163082016C126322002 @default.
• W2163082016 hasConceptScore W2163082016C142462285 @default.
• W2163082016 hasConceptScore W2163082016C203014093 @default.
• W2163082016 hasConceptScore W2163082016C2522874641 @default.
• W2163082016 hasConceptScore W2163082016C2776408679 @default.
• W2163082016 hasConceptScore W2163082016C2776455275 @default.
• W2163082016 hasConceptScore W2163082016C2777075537 @default.
• W2163082016 hasConceptScore W2163082016C2777100407 @default.
• W2163082016 hasConceptScore W2163082016C2777214474 @default.
• W2163082016 hasConceptScore W2163082016C2778019345 @default.
• W2163082016 hasConceptScore W2163082016C2778785139 @default.
• W2163082016 hasConceptScore W2163082016C2778867932 @default.
• W2163082016 hasConceptScore W2163082016C2779298103 @default.
• W2163082016 hasConceptScore W2163082016C2780040827 @default.
• W2163082016 hasConceptScore W2163082016C2993143319 @default.
• W2163082016 hasConceptScore W2163082016C71924100 @default.
• W2163082016 hasLocation W21630820161 @default.
• W2163082016 hasOpenAccess W2163082016 @default.
• W2163082016 hasPrimaryLocation W21630820161 @default.
• W2163082016 hasRelatedWork W1551144440 @default.
• W2163082016 hasRelatedWork W1715619413 @default.
• W2163082016 hasRelatedWork W1973675889 @default.
• W2163082016 hasRelatedWork W2009539712 @default.
• W2163082016 hasRelatedWork W2043193067 @default.
• W2163082016 hasRelatedWork W2074211702 @default.
• W2163082016 hasRelatedWork W2080672894 @default.
• W2163082016 hasRelatedWork W2092858485 @default.
• W2163082016 hasRelatedWork W2113428683 @default.
• W2163082016 hasRelatedWork W2117223055 @default.
• W2163082016 hasRelatedWork W2152520426 @default.
• W2163082016 hasRelatedWork W2184522727 @default.
• W2163082016 hasRelatedWork W2275203344 @default.
• W2163082016 hasRelatedWork W2417556805 @default.
• W2163082016 hasRelatedWork W2418652184 @default.
• W2163082016 hasRelatedWork W2473571388 @default.
• W2163082016 hasRelatedWork W2744255615 @default.
• W2163082016 hasRelatedWork W2922793732 @default.
• W2163082016 hasRelatedWork W3214363948 @default.
• W2163082016 hasRelatedWork W82172957 @default.
• W2163082016 hasVolume "8" @default.
• W2163082016 isParatext "false" @default.
• W2163082016 isRetracted "false" @default.
• W2163082016 magId "2163082016" @default.
• W2163082016 workType "article" @default.